Identification of Risk Phenotypes for Sarcopenia Using DXA WBC, Anthropometric and MA Among Young Adults

December 14, 2024 updated by: Muhammad Naveed Babur, Superior University

Identification of Risk Phenotypes for Sarcopenia Using DXA Whole Body Composition, Anthropometric and Muskuloskeltal Analysis Among Young Adults

This cross-sectional study aims to identify risk phenotypes for sarcopenia among young adults using Dual-energy X-ray Absorptiometry (DXA) for whole-body composition analysis, along with anthropometric and musculoskeletal assessments. Sarcopenia, characterized by the loss of muscle mass and strength, is a growing concern, particularly among the aging population.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

However, early identification in young adults can allow for preventive strategies to improve long-term health outcomes. This study, involving 221 participants aged 15 to 35, focuses on assessing the correlation between DXA-derived body composition, musculoskeletal fitness, and anthropometric measurements with sarcopenia risk. Primary outcome measures include DXA imaging and dynamometry for body composition and strength evaluation, while secondary outcomes focus on detailed anthropometric and musculoskeletal analyses. By addressing early risk factors in younger populations, this research hopes to enhance understanding of sarcopenia's development and support early intervention strategies. Data collection is conducted at the Center of Nuclear Medicine in Lahore, Pakistan.

Study Type

Observational

Enrollment (Actual)

221

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • CENUM Center Mayo Hospital Rd, Anarkali Bazaar

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

This cross-sectional study aims to identify risk phenotypes for sarcopenia among young adults using Dual-energy X-ray Absorptiometry (DXA) for whole-body composition analysis, along with anthropometric and musculoskeletal assessments.

Description

Inclusion Criteria:

  • Young Adults ( between 15-35) (7)

Exclusion Criteria:

  • Elderly Patients
  • Children below the age of 18 Years
  • Diagnosed Malignancy
  • Diagnosed Patients
  • Diseased Individuals such as Chronic Illness and Malignancies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group
Combination product: Identification of Risk Phenotypes of Sarcopenia
Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
DXA
Time Frame: 12 Months
DXA Whole Body Imaging is a primary tool of measure for my study
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Superior University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 28, 2024

Primary Completion (Actual)

May 31, 2024

Study Completion (Estimated)

March 1, 2025

Study Registration Dates

First Submitted

December 14, 2024

First Submitted That Met QC Criteria

December 14, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 14, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MSAHS/Batch-Fall22/002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe